IOVANCE BIOTHERAPEUTICS, INC. annual report, FY2012

Business context and reporting period

The supplied filing is Genesis Biopharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2012—not an Iovance Biotherapeutics filing or a standalone fourth-quarter report. The company was a development-stage biotechnology business developing Cōntego, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, initially for metastatic melanoma. It had no product revenue and no FDA-approved product. The filing describes later 2013 transactions, including a merger with Lion Biotechnologies and a planned company name change.

Financial performance and position

The 2012 net loss was substantially smaller mainly because the company recorded an $8.635 million gain from a decrease in the fair value of derivative liabilities. This non-cash gain more than offset part of the operating loss; it should not be read as operating improvement or revenue. Other notable 2012 costs included $1.922 million of interest expense, $1.390 million of financing costs, and $4.203 million of non-cash share-based compensation. Profit margins are not meaningful with no revenue.

At December 31, 2012, cash and cash equivalents were zero; current assets were $7,275 and total assets were $29,413. Current liabilities were $11.349 million, working capital deficiency was $11.342 million, and stockholders’ deficiency was $11.319 million. Notes payable totaled $6.481 million principal, with $2.029 million in accrued interest and penalties; the company reported that the notes were in default. The filing does not provide a meaningful debt-to-equity or revenue-margin measure given the negative equity and absence of revenue. It reports no off-balance-sheet arrangements.

Material changes and subsequent events

• Operating expenses fell $12.826 million year over year, principally because non-cash compensation declined from $14.608 million to $4.203 million and legal and professional costs decreased.
• Operating cash use improved by $3.948 million versus 2011, but the company ended 2012 with no cash and significant overdue liabilities.
• In May 2013, the company restructured debt and equity securities. Debt and related obligations were converted into common shares, extinguishing substantial liabilities and removing liens; the filing reports approximately $8.4 million of debt and accrued amounts converted. It also raised funds through share sales. The filing gives differing proceeds descriptions: approximately $1.25 million in narrative disclosures and $1.35 million gross/$1.24 million net in the pro forma discussion.
• In July 2013, the company acquired Lion Biotechnologies, Inc. for 134 million shares, with up to 135 million additional shares contingent on milestones. New management and board appointments followed. A reverse split, corporate name change to Lion Biotechnologies, and authorized-share and equity-plan changes were approved and expected to take effect by the end of September 2013.

Outlook, commentary, and principal risks

Management expected continued losses and no product or licensing revenue in 2013 or the foreseeable future. It projected approximately $5–6 million of R&D spending in 2013 and estimated about $15 million would be needed over the following two years for additional clinical trials. The five-year NCI cooperative research agreement required $1 million annually, payable quarterly. The TIL program remained dependent on development, clinical evidence, regulatory approval, and the ability to establish scalable manufacturing with third parties, including Lonza.

The auditor’s report and management disclosures raised substantial doubt about the company’s ability to continue as a going concern. Management said available cash was insufficient and additional financing was necessary; funding was not committed. The company also disclosed approximately $682,000 past due to NIH under its license and a 2013 CRADA payment default, with discussions underway to cure the defaults. NIH termination of the license could prevent the planned Cōntego program. Other key risks include clinical and regulatory failure or delay, manufacturing scale-up and cost uncertainty, reliance on non-exclusive NIH intellectual property and external partners, competition, dilution and anti-dilution provisions, and limited trading liquidity.

The company reported ineffective disclosure controls and internal control over financial reporting at year-end 2012, citing insufficient accounting personnel and inadequate controls over securities issuance and related disclosures. Management planned remediation, but completion and effectiveness were not established in this filing.

Important facts for investors to verify

• Confirm issuer identity and filing: the provided document is Genesis Biopharma’s 2012 10-K, notwithstanding the Iovance company metadata.
• Reconcile the 2013 financing totals and share counts across the restructuring disclosures, pro forma statements, and subsequent filings.
• Verify the status and cure of NIH license and NCI CRADA defaults, and whether the license and research arrangements remained in force.
• Check post-restructuring cash, liabilities, financing commitments, and the company’s going-concern position; the 2012 balance sheet itself showed no cash.
• Confirm subsequent clinical-trial progress, regulatory status, manufacturing readiness and costs, and any changes to projected R&D spending.
• Review dilution exposure, including milestone shares, financing-linked share awards, authorized-share changes, reverse-split implementation, and remaining anti-dilution rights.
• Determine whether management’s planned internal-control remediation was completed and whether later filings reported effective controls.